JPH10158177A - Itching and / or pain inhibitor - Google Patents
Itching and / or pain inhibitorInfo
- Publication number
- JPH10158177A JPH10158177A JP8317696A JP31769696A JPH10158177A JP H10158177 A JPH10158177 A JP H10158177A JP 8317696 A JP8317696 A JP 8317696A JP 31769696 A JP31769696 A JP 31769696A JP H10158177 A JPH10158177 A JP H10158177A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- water
- pain
- natural product
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
(57)【要約】
【解決手段】 補骨脂、大黄、シルク、熊笹及び桑から
選ばれる1種もしくは2種以上の天然物又はその抽出物
を含有する痒み及び/又は痛み抑制剤。
【効果】 サブスタンスP拮抗作用が強く、安全性も高
い。(57) Abstract: An agent for suppressing itch and / or pain, comprising one or more natural products selected from chondrogenic fat, rhubarb, silk, Kumasa and mulberry, or an extract thereof. [Effect] Strong substance P antagonism and high safety.
Description
【0001】[0001]
【発明の属する技術分野】本発明はサブスタンスP拮抗
作用を有する痒み及び/又は痛み抑制剤に関する。The present invention relates to a pruritus and / or pain inhibitor having a substance P antagonistic action.
【0002】[0002]
【従来の技術】サブスタンスPは回腸収縮作用、唾液分
泌促進作用、痛覚の刺激作用等を有することが知られて
いる11個のアミノ酸からなるペプチドである。このサ
ブスタンスPは、近年ではタキキニン類の一種として位
置づけられている。2. Description of the Related Art Substance P is a peptide consisting of 11 amino acids which is known to have an ileal contraction action, a saliva secretion promoting action, a pain stimulating action and the like. This substance P has recently been positioned as a kind of tachykinins.
【0003】このサブスタンスPは、消化器系疾患、神
経系疾患、循環器系疾患など広い範囲で作用しているこ
とが知られているが、特にハンチントン舞踏病、カルチ
ノイド症候群、慢性疼痛、皮膚血管透過性亢進等におい
て深く関与すると考えられている。[0003] This substance P is known to act in a wide range of diseases such as digestive diseases, nervous system diseases, and circulatory system diseases. In particular, Huntington's disease, carcinoid syndrome, chronic pain, and cutaneous blood vessels It is thought to be deeply involved in permeability enhancement and the like.
【0004】これらサブスタンスPの関与する疾患の治
療薬を開発する目的で種々のサブスタンスP拮抗剤が報
告されている(M. M. Chang, S. E. Leeman, H. D. Nia
ll,Nature New Biol., 232, 86(1971)、Hugan R. M. et
al, Br. J. Pharmacol., 99(Suppl.), 62P(1990))。[0004] Various substance P antagonists have been reported for the purpose of developing therapeutic agents for these diseases involving substance P (MM Chang, SE Leeman, HD Nia).
ll, Nature New Biol., 232, 86 (1971), Hugan RM et
al, Br. J. Pharmacol., 99 (Suppl.), 62P (1990)).
【0005】[0005]
【発明が解決しようとする課題】しかしながら、これら
従来のサブスタンスP拮抗剤は合成ペプチドであり、ア
ゴニスト作用及びヒトに対する抗原性を有するため、安
全性の面から医薬として開発されるには至っておらず、
サブスタンスPの関与する痒み・痛みを抑制する薬剤も
開発されていない。従って本発明の目的は優れたサブス
タンスP拮抗作用を有するとともに安全性の高い痒み及
び/又は痛み抑制剤を提供することにある。However, since these conventional substance P antagonists are synthetic peptides and have an agonistic activity and antigenicity against humans, they have not been developed as drugs from the viewpoint of safety. ,
No drug has been developed to suppress itching and pain involving substance P. Accordingly, an object of the present invention is to provide a highly safe pruritus and / or pain inhibitor having excellent substance P antagonistic activity.
【0006】[0006]
【課題を解決するための手段】そこで本発明者らは前記
課題を解決すべく広く植物の抽出物についてその薬理作
用を検討してきたところ、食品等として使用されている
安全性の高い後述する植物又はその抽出物が、特に皮膚
において優れたサブスタンスP拮抗作用を有することを
見出し、本発明を完成するに至った。Means for Solving the Problems The present inventors have studied the pharmacological action of plant extracts widely to solve the above-mentioned problems. Alternatively, the inventors have found that the extract has an excellent substance P antagonistic effect particularly on the skin, and have completed the present invention.
【0007】すなわち、本発明は補骨脂、大黄、シル
ク、熊笹及び桑から選ばれる1種もしくは2種以上の天
然物又はその抽出物を含有する痒み及び/又は痛み抑制
剤を提供するものである。[0007] That is, the present invention provides an itch and / or pain inhibitor containing one or more natural products or extracts thereof selected from chondrogenic fat, rhubarb, silk, Kumasa and mulberry. is there.
【0008】[0008]
【発明の実施の形態】本発明で用いる天然物のうち植物
とは、それらの全草又はそれらの葉、茎、根、果実、種
子及び花のうちの1又は2以上の箇所(以下「原体」と
称する)又はこれを乾燥して粉砕したものであり、植物
抽出物とは、原体を乾燥し又は乾燥することなく粉砕し
た後、室温又は加温下に溶剤により抽出するか又はソッ
クスレー抽出器等の抽出器具を用いて抽出することによ
り得られる各種溶媒抽出液、その希釈液、その濃縮液、
あるいはその乾燥末を意味するものである。本発明にお
いては、補骨脂は成熟種子、大黄は根茎、シルクは絹繊
維、熊笹は樹皮、桑は葉の乾燥物又はその抽出物を用い
ることが好ましい。本発明において、これらの天然物又
はその抽出物は1種又は2種以上を用いることができ
る。BEST MODE FOR CARRYING OUT THE INVENTION Plants among natural products used in the present invention are plants or whole plants or one or more of leaves, stems, roots, fruits, seeds and flowers (hereinafter referred to as "primary plants"). ) Or dried and ground, and plant extracts are dried or ground without drying and then extracted with a solvent at room temperature or under heating, or by Soxhlet. Various solvent extracts obtained by extraction using an extraction device such as an extractor, a diluent thereof, a concentrate thereof,
Or it means the dry powder. In the present invention, it is preferable to use matured seeds for rheumatoid arthritis, rhizomes for rhubarb, silk fibers for silk, bark for Kumasa, and dried leaves or extracts of mulberry for mulberry. In the present invention, one or more of these natural products or extracts thereof can be used.
【0009】これらの天然物からの抽出は、有効成分を
効率的に得る為に、水及び/又は水溶性有機溶媒を用い
て行なうことが必要である。ここで用いられる水溶性有
機溶媒としては、例えばメタノール、エタノール、プロ
パノール、ブタノール、プロピレングリコール、1,3
−ブチレングリコール等が挙げられるが、就中、エタノ
ール、ブタノール、プロピレングリコール、1,3−ブ
チレングリコールが好ましい。水溶性有機溶媒は1種又
は2種以上を混合して用いてもよく、更に水と組み合せ
ることが好ましい。上記植物に対する溶媒の量は1〜2
0重量倍とすることが好ましい。Extraction from these natural products requires the use of water and / or a water-soluble organic solvent in order to obtain an effective ingredient efficiently. Examples of the water-soluble organic solvent used here include methanol, ethanol, propanol, butanol, propylene glycol, 1,3
-Butylene glycol and the like, among which ethanol, butanol, propylene glycol and 1,3-butylene glycol are preferred. The water-soluble organic solvent may be used singly or as a mixture of two or more kinds, and is preferably combined with water. The amount of the solvent for the plant is 1-2.
It is preferably 0 times by weight.
【0010】一方、原料となる上記天然物は、そのまま
抽出に用いるより、粗末又は粉末とすることが好まし
い。上記天然物は上記抽出溶媒に浸漬し、常法により抽
出を行なえばよいが、必要に応じて50℃程度まで加温
して抽出効率を高めてもよい。また、抽出物をそのまま
又は濃縮した後、溶媒で分画し、有効画分のみ取り出す
と、より少量で高い効果を期待することができる。ここ
で分画に用いる溶媒としては、水と酢酸エチルが好まし
く、この水画分を用いることが好ましい。On the other hand, the above-mentioned natural product as a raw material is preferably made into a coarse powder or a powder, rather than used for extraction as it is. The above-mentioned natural product may be immersed in the above-mentioned extraction solvent and may be extracted by a conventional method. However, if necessary, it may be heated to about 50 ° C. to increase the extraction efficiency. If the extract is directly or concentrated and then fractionated with a solvent, and only an effective fraction is taken out, a higher effect can be expected with a smaller amount. Here, as the solvent used for fractionation, water and ethyl acetate are preferable, and this water fraction is preferably used.
【0011】上記天然物又はその抽出物は、サブスタン
スPによる皮膚血管透過性亢進を抑制する作用を有す
る。従って、上記植物又はその抽出物を含有する本発明
の痒み及び/又は痛み抑制剤は、特に皮膚における各種
炎症症状の治療薬として有用である。The above-mentioned natural product or its extract has an effect of suppressing the increase in cutaneous vascular permeability caused by substance P. Therefore, the agent for suppressing itch and / or pain of the present invention containing the plant or its extract is useful as a therapeutic agent for various inflammatory conditions particularly in the skin.
【0012】本発明の痒み抑制剤は、上記天然物又はそ
の抽出物を配合する限りいかなる形態でもよいが、錠
剤、顆粒剤、カプセル剤等の経口投与用製剤;注射剤;
軟膏クリーム、ローション、ゲル等の外用剤;浴用剤等
として用いることができる。これらの製剤とするには、
上記天然物又はその抽出物と賦形剤、増量剤、結合剤、
湿潤化剤、崩壊剤、界面活性剤、滑沢剤、分散剤、緩衝
剤、保存剤、矯味剤、香料、被覆剤等を適宜組み合わせ
て処方することにより製造することができる。また入浴
剤とするには、これらの添加剤に加え、無機塩類、炭酸
ガス、炭酸ガス発生物を配合せしめることができる。The pruritus suppressant of the present invention may be in any form as long as it contains the above-mentioned natural product or its extract. Oral preparations such as tablets, granules and capsules; injections;
External preparations such as ointment creams, lotions and gels; can be used as bath preparations and the like. To make these preparations,
The natural product or its extract and excipient, extender, binder,
It can be produced by appropriately combining a wetting agent, a disintegrant, a surfactant, a lubricant, a dispersant, a buffer, a preservative, a flavoring agent, a fragrance, a coating agent and the like. In addition, in order to use as a bathing agent, inorganic salts, carbon dioxide, and a carbon dioxide generator can be added to these additives.
【0013】本発明の痒み及び/又は痛み抑制剤の投与
量は、症状、投与ルート等によっても異なるが、一般に
成人に対して上記天然物抽出物(乾燥重量)として10
〜5,000mg、特に50〜2,000mgを通常1日1
〜4回に分けて投与するのが好ましい。また、入浴剤と
して使用する場合は、特に限定されないが、標準的な浴
水150〜200L当り、上記天然物の原体の粉末(原
末)0.001〜1,000gから得られる抽出物の量
とすることが好ましく、更に原末0.01〜100gか
ら得られる抽出物の量とすることが好ましい。The dosage of the pruritus and / or pain inhibitor of the present invention varies depending on symptoms, administration route, etc., but is generally 10% as the above natural product extract (dry weight) for adults.
5,000 mg, especially 50 to 2,000 mg, usually 1 day
It is preferable to administer in 4 to 4 divided doses. When used as a bathing agent, there is no particular limitation, but the extract obtained from 0.001 to 1,000 g of the above-mentioned natural product powder (raw powder) per 150 to 200 L of standard bath water is used. Preferably, the amount is an extract obtained from 0.01 to 100 g of the bulk powder.
【0014】[0014]
【発明の効果】本発明の痒み及び/又は痛み抑制剤は、
安全性が高く、かつサブスタンスP拮抗作用が強いので
サブスタンスPが関与する疾患に基づく痒み及び/又は
痛み、特に皮膚炎症に基づく痒み及び/又は痛みの治療
剤として有用である。The itch and / or pain inhibitor of the present invention comprises
Since it is highly safe and has a strong substance P antagonistic effect, it is useful as a therapeutic agent for itch and / or pain due to a disease involving substance P, especially itch and / or pain due to skin inflammation.
【0015】[0015]
【実施例】次に実施例、試験例を挙げて本発明を説明す
るが、本発明はこれらの実施例に限定されるものではな
い。Next, the present invention will be described with reference to examples and test examples, but the present invention is not limited to these examples.
【0016】製造例1 補骨脂抽出物 オランダビユ(Psoralea corylifolia)の熟成種子を細
切し、その10gに水とエタノールの混液(50:5
0)100mlを加え浸漬した。これを濾過し補骨脂抽出
物を得た。Production Example 1 Bone Bone Extract Extract Mature seeds of Dutch beaulace ( Psoralea corylifolia ) were minced, and 10 g of the mixture was mixed with water and ethanol (50: 5).
0) 100 ml was added and immersed. This was filtered to obtain an osteoclast extract.
【0017】製造例2 大黄抽出物 大黄(Rheum palmatum)の根茎を細切し、その10gに
水とエタノールの混液(58:42)100mlを加え浸
漬した。これを濾過し大黄抽出物を得た。Production Example 2 Rhubarb Extract Rhizome of rhubarb ( Rheum palmatum ) was cut into small pieces, and 10 g of the rhizome was immersed in 100 ml of a mixture of water and ethanol (58:42). This was filtered to obtain a rhubarb extract.
【0018】製造例3 シルク抽出物 絹繊維10gを1N塩酸10mlと水とエタノールの混液
(50:50)100mlを加え浸漬した。これを濾過し
シルク抽出物を得た。Production Example 3 Silk extract 10 g of silk fiber was immersed in 10 ml of 1N hydrochloric acid, 100 ml of a mixture of water and ethanol (50:50). This was filtered to obtain a silk extract.
【0019】製造例4 熊笹抽出物 クマザサ(Sasa albo-marginata)の樹皮を細切し、そ
の10gに水とエタノールの混液(70:30)100
mlを加え浸漬した。これを濾過し熊笹抽出物を得た。Production Example 4 Kuma-basa extract Extract The bark of Kumazasa ( Sasa albo-marginata ) was cut into small pieces, and 10 g of the bark was mixed with 100 parts of a mixture of water and ethanol (70:30).
ml was added and immersed. This was filtered to obtain a Kumasa bamboo extract.
【0020】製造例5 桑抽出物 トウグワ(Morus alba)の葉を細切し、その10gに水
とエタノールの混液(50:50)100mlを加え浸漬
した。これを濾過し桑抽出物を得た。Production Example 5 Mulberry Extract Leaves of Morus alba were cut into small pieces, and 10 g of the leaves were immersed in 100 ml of a mixture of water and ethanol (50:50). This was filtered to obtain a mulberry extract.
【0021】試験例1 モルモット背部を剃毛し、被験エキス溶液(生理食塩水
で濃度500μg(固形分重量)/mlに希釈する)10
0μl皮内投与し、6時間後にエバンスブルー(生理食
塩水に溶解、5mg/ml、モルモット体重1kg当たり0.
5ml)を静脈内投与した。次いで先の被験物質皮内投与
部位に、被験エキス溶液50μl及びサブスタンスP溶
液(10-5M)50μlを皮内投与した。20分後に、
モルモット背部の皮膚を剥ぎ、裏側から色素(エバンス
ブルー)が漏出している面積を測定した。その結果、表
1に示す如く、本発明における天然物抽出物はサブスタ
ンスPによる血管透過性亢進作用を抑制することがわか
る。Test Example 1 The back of a guinea pig was shaved, and a test extract solution (diluted with physiological saline to a concentration of 500 μg (solid content weight) / ml) 10
0 μl intradermally, and 6 hours later, Evans Blue (dissolved in physiological saline, 5 mg / ml, 0.1 mg / kg guinea pig body weight).
5 ml) was administered intravenously. Next, 50 μl of the test extract solution and 50 μl of the substance P solution (10 −5 M) were intradermally administered to the site of intradermal administration of the test substance. 20 minutes later,
The skin on the back of the guinea pig was peeled off, and the area where the pigment (Evans blue) leaked from the back side was measured. As a result, as shown in Table 1, it can be seen that the natural product extract of the present invention suppresses the vascular permeability enhancing effect of substance P.
【0022】[0022]
【表1】 [Table 1]
【0023】試験例2 天然物抽出物による痒み抑制効
果 7〜10週齢雌性WBN/ILA−HT系ヘアレスラッ
トを個別ケージに入れ、1時間環境に馴化させた後、背
部右側に評価天然物抽出物500μg(固形分重量)/
ml又は生理食塩水(溶媒)を50μl/site塗布した。
背部左側については処置を施さなかった。6時間後、塗
布した背部右側に評価天然物抽出物(500μg/ml:
50μl/site)の塗布及び起痒物質(サブスタンスP
10−5M:50μl/site)の皮内投与を行ない、9
0分間、8mmビデオカメラで撮影し、投与部位側及び無
処置側の掻き・舐め時間を測定した。評価の指標として
は、グルーミングの影響を取り除くために、試験部位
(右側)の掻き・舐め時間を無処置部(左側)の掻き・
舐め時間で割ることによって掻き頻度を算出し、効力評
価を行なった。その結果、本発明における天然物抽出物
は、優れた痒み抑制効果を有することが確認された。Test Example 2 Itching-inhibiting effect of natural product extract 7- to 10-week-old female WBN / ILA-HT hairless rats were placed in individual cages, allowed to acclimate to the environment for 1 hour, and evaluated for evaluation of natural products on the right side of the back. 500 μg (solid content weight) /
ml or physiological saline (solvent) was applied at 50 μl / site.
No treatment was performed on the left back. After 6 hours, the applied natural product extract (500 μg / ml:
50 μl / site) and pruritic substance (substance P)
10-5M: 50 μl / site) was administered intradermally, and 9
The images were taken with an 8 mm video camera for 0 minutes, and the scraping and licking times on the administration site side and the untreated side were measured. As an index of evaluation, in order to remove the effect of grooming, the time of scraping and licking of the test site (right) was
The scratching frequency was calculated by dividing by the licking time, and the efficacy was evaluated. As a result, it was confirmed that the natural product extract of the present invention had an excellent itch suppressing effect.
【0024】[0024]
【表2】 [Table 2]
【0025】試験例3 天然物抽出物による痛み抑制効
果 Randall-Selitto 法により本発明における天然物抽出物
を評価した。すなわち、5週齢SD系雄性ラットに、エ
ーテル麻酔下にて左後肢足底皮内に流動パラフィンに懸
濁せしめたMycobacterium butyricum 0.6mg/0.1
ml/headを注射した(第0日目)。第14日目に右後肢
の疼痛閥値の測定(UGO BASILE社製疼痛閥値測定装置を
使用)を行ない、平均値がほぼ均一となるように群分け
し、その日より1日1回、連日植物抽出物を右後肢に塗
布した。第28日目に右後肢の疼痛閥値を再び測定し、
疼痛を感じる加重値の差により鎮痛効果を評価した。そ
の結果、本発明における天然物抽出物は、優れた痛み抑
制効果を有することが確認された。Test Example 3 Pain Suppressing Effect of Natural Product Extract The natural product extract of the present invention was evaluated by the Randall-Selitto method. That is, a 5-week-old male SD rat was Mycobacterium butyricum 0.6 mg / 0.1 suspended in liquid paraffin in the sole of the left hind limb under ether anesthesia.
ml / head was injected (day 0). On the 14th day, the pain level of the right hind limb was measured (using a pain level measuring device manufactured by UGO BASILE), and divided into groups so that the average value was almost uniform. The plant extract was applied to the right hind limb. On day 28, the pain crest value of the right hind limb was measured again,
The analgesic effect was evaluated based on the difference in weight at which pain was felt. As a result, it was confirmed that the natural product extract of the present invention had an excellent pain suppressing effect.
【0026】[0026]
【表3】 [Table 3]
【0027】実施例1(錠剤) 下記組成の錠剤を直接圧縮成形により製造した。 補骨脂抽出物(製造例1) 100mg 結晶セルロース 393mg 乳糖 100mg ヒドロキシプロピルセルロース−L 4mg ステアリン酸マグネシウム 3mg 全 量 500mgExample 1 (Tablets) Tablets having the following composition were produced by direct compression molding. Bone fat extract (Production Example 1) 100 mg Crystalline cellulose 393 mg Lactose 100 mg Hydroxypropylcellulose-L 4 mg Magnesium stearate 3 mg Total amount 500 mg
【0028】実施例2(顆粒剤) 下記成分を均一に混合し、捏和し、押し出し造粒機によ
り造粒し、篩別して顆粒剤を得た。 (成分) (g) 熊笹抽出物(製造例4) 10 結晶セルロース 50 10%ヒドロキシプロピルセルロース 40 計 100Example 2 (Granules) The following components were uniformly mixed, kneaded, granulated by an extrusion granulator, and sieved to obtain granules. (Ingredients) (g) Kuma-basa extract (Production Example 4) 10 Microcrystalline cellulose 50 10% Hydroxypropylcellulose 40 Total 100
【0029】実施例3(噴霧剤) 下記成分を1ボンベ中に含む噴霧剤を常法により製造し
た。 (成分) (g) 大黄抽出物(製造例2) 1 オレイン酸 3 フレオン11 1.2 フレオン12 2.5 フレオン114 1.3 計 9Example 3 (Spray) A spray containing the following components in one cylinder was produced by a conventional method. (Components) (g) Rhubarb extract (Production Example 2) 1 Oleic acid 3 Freon 11 1.2 Freon 12 2.5 Freon 114 1.3 Total 9
【0030】実施例4(軟膏剤) 下記成分を均一に混合し、軟膏剤を得た。 (成分) (g) シルク抽出物(製造例3) 10 スクワラン 20 グリセリン 20 セチルアルコール 5 マグネシウムステアレート 3 プロピレングリコール 5 水 20 エタノール 7 計 90Example 4 (Ointment) The following components were uniformly mixed to obtain an ointment. (Components) (g) Silk extract (Production Example 3) 10 Squalane 20 Glycerin 20 Cetyl alcohol 5 Magnesium stearate 3 Propylene glycol 5 Water 20 Ethanol 7 Total 90
【0031】実施例5(カプセル剤) 下記成分を均一に混合し、カプセル剤を得た。 (成分) (g) 桑抽出物(製造例5) 100 結晶セルロース 100 乳糖 150 軽質無水ケイ酸 20 計 370Example 5 (Capsule) The following components were uniformly mixed to obtain a capsule. (Components) (g) Mulberry extract (Production Example 5) 100 Crystalline cellulose 100 Lactose 150 Light anhydrous silicic acid 20 Total 370
【0032】実施例6(クリーム) 下記成分を均一に混合し、クリームを得た。 (成分) (g) 補骨脂抽出物(製造例1) 1 コレステロール 0.5 コレステリルイソステアレート 1 ポリエーテル変性シリコーン 1.5 環状シリコーン 20 メチルフェニルポリシロキサン 2 メチルポリシロキサン 2 硫酸マグネシウム 0.5 55%エタノール 5 カルボキシメチルキチン 0.5 精製水 66 計 100Example 6 (Cream) The following ingredients were uniformly mixed to obtain a cream. (Components) (g) Bone cartilage extract (Production Example 1) 1 Cholesterol 0.5 Cholesteryl isostearate 1 Polyether-modified silicone 1.5 Cyclic silicone 20 Methylphenylpolysiloxane 2 Methylpolysiloxane 2 Magnesium sulfate 0.5 55% ethanol 5 carboxymethyl chitin 0.5 purified water 66 total 100
【0033】 実施例7(スキンローション) (成分) (g) シルク抽出物(製造例3) 2 グリセリンモノステアレート 1 エタノール 15 プロピレングリコール 4 イソプロピルパルミテート 3 ラノリン 1 パラオキシ安息香酸メチル 0.1 セラミド 1 香料,色素 微量 精製水 残量 計 100.0Example 7 (Skin Lotion) (Components) (g) Silk Extract (Production Example 3) 2 Glycerin Monostearate 1 Ethanol 15 Propylene Glycol 4 Isopropyl Palmitate 3 Lanolin 1 Methyl Paraoxybenzoate 0.1 Ceramide 1 Perfume and pigment Trace purified water Fuel gauge 100.0
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 35/78 ADA A61K 35/78 ADAU AED AEDC (72)発明者 金澤 聡 栃木県芳賀郡市貝町赤羽2606 花王株式会 社研究所内 (72)発明者 西澤 義則 栃木県芳賀郡市貝町赤羽2606 花王株式会 社研究所内──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification symbol FI A61K 35/78 ADA A61K 35/78 ADAU AED AEDC (72) Inventor Satoshi Kanazawa 2606 Akabane, Kakaicho, Haga-gun, Tochigi Pref. Research by Kao Corporation (72) Inventor Yoshinori Nishizawa 2606 Akabane, Kaigamachi, Haga-gun, Tochigi Pref.
Claims (3)
選ばれる1種もしくは2種以上の天然物又はその抽出物
を含有する痒み及び/又は痛み抑制剤。1. An itching and / or pain suppressant comprising one or more natural products selected from chondrogenic fat, rhubarb, silk, Kumasa and mulberry, or an extract thereof.
/及び水溶性有機溶媒を用いて抽出した抽出物である請
求項1記載の痒み及び/又は痛み抑制剤。2. The agent for suppressing itch and / or pain according to claim 1, wherein the natural product extract is an extract extracted from the natural product using water and / or a water-soluble organic solvent.
機溶媒を用いて抽出したものを水と酢酸エチルで分画し
て得られた水画分である請求項1記載の痒み及び/又は
痛み抑制剤。3. The itch according to claim 1, wherein the natural product extract is a water fraction obtained by fractionating water and / or a water-soluble organic solvent extracted with water and ethyl acetate. // Pain suppressants.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8317696A JPH10158177A (en) | 1996-11-28 | 1996-11-28 | Itching and / or pain inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8317696A JPH10158177A (en) | 1996-11-28 | 1996-11-28 | Itching and / or pain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10158177A true JPH10158177A (en) | 1998-06-16 |
Family
ID=18091013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8317696A Pending JPH10158177A (en) | 1996-11-28 | 1996-11-28 | Itching and / or pain inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10158177A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10158179A (en) * | 1996-11-28 | 1998-06-16 | Kao Corp | External preparation for skin |
| US6482420B2 (en) | 2000-12-27 | 2002-11-19 | Noboru Huziwara | Composition having bactericidal action, cosmetics containing said composition and ultraviolet ray screening agent |
| EP1506782A1 (en) * | 2003-08-11 | 2005-02-16 | I-Hung Chu | Vapor fraction from seeds of glycine max (L.) merr. and composition thereof |
| JP2006241018A (en) * | 2005-03-01 | 2006-09-14 | Hoodo:Kk | Promoting agent of new hair growth, white hair preventing and/or treating agent, antipruritic composition, and wound healing accelerating agent |
| US7112344B2 (en) | 2003-08-11 | 2006-09-26 | I-Hung Chu | Vapor fraction from seeds of Glycine max (L.)Merr. and composition thereof |
| US7282226B2 (en) | 2003-08-11 | 2007-10-16 | I-Hung Chu | Vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof |
| JP2010209019A (en) * | 2009-03-11 | 2010-09-24 | Kazuo Fukuda | Plaster for affected part having analgesic action, and method of using the same |
| JP2011088846A (en) * | 2009-10-21 | 2011-05-06 | Kazuo Fukuda | Affected-part patch having analgesic action, and method for using the same |
| JP2011162507A (en) * | 2010-02-12 | 2011-08-25 | Pias Arise Kk | Inhibitor of extension/stimulation-mediated production of collagen decomposition enzyme |
| JP4976636B2 (en) * | 2000-07-26 | 2012-07-18 | 株式会社鳳凰堂 | Antipruritic composition and composition for promoting wound healing |
-
1996
- 1996-11-28 JP JP8317696A patent/JPH10158177A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10158179A (en) * | 1996-11-28 | 1998-06-16 | Kao Corp | External preparation for skin |
| JP4976636B2 (en) * | 2000-07-26 | 2012-07-18 | 株式会社鳳凰堂 | Antipruritic composition and composition for promoting wound healing |
| US6482420B2 (en) | 2000-12-27 | 2002-11-19 | Noboru Huziwara | Composition having bactericidal action, cosmetics containing said composition and ultraviolet ray screening agent |
| EP1506782A1 (en) * | 2003-08-11 | 2005-02-16 | I-Hung Chu | Vapor fraction from seeds of glycine max (L.) merr. and composition thereof |
| US7112344B2 (en) | 2003-08-11 | 2006-09-26 | I-Hung Chu | Vapor fraction from seeds of Glycine max (L.)Merr. and composition thereof |
| US7282226B2 (en) | 2003-08-11 | 2007-10-16 | I-Hung Chu | Vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof |
| JP2006241018A (en) * | 2005-03-01 | 2006-09-14 | Hoodo:Kk | Promoting agent of new hair growth, white hair preventing and/or treating agent, antipruritic composition, and wound healing accelerating agent |
| JP2010209019A (en) * | 2009-03-11 | 2010-09-24 | Kazuo Fukuda | Plaster for affected part having analgesic action, and method of using the same |
| JP2011088846A (en) * | 2009-10-21 | 2011-05-06 | Kazuo Fukuda | Affected-part patch having analgesic action, and method for using the same |
| JP2011162507A (en) * | 2010-02-12 | 2011-08-25 | Pias Arise Kk | Inhibitor of extension/stimulation-mediated production of collagen decomposition enzyme |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5080901A (en) | Cosmetic and paramedicinal compositions containing plant extracts | |
| KR102309958B1 (en) | A cosmetic composition for skin improvement comprising bulb extract | |
| KR102142930B1 (en) | A composition for promoting melanin synthesis comprising flower extract of milk thistle | |
| US12303588B2 (en) | Composition containing Cirsium japonicum extract as active ingredient for stimulating melanogenesis | |
| KR101086504B1 (en) | Composition for skin application having improved blood circulation and vasodilation | |
| JP2001163794A (en) | Promoter for production of hyaluronic acid and preparation for external use for skin | |
| KR102189330B1 (en) | A cosmetic composition for skin improvement comprising bulb extract | |
| JPH10158177A (en) | Itching and / or pain inhibitor | |
| KR100999870B1 (en) | Pharmaceutical composition for preventing and treating allergic skin diseases, containing Echo and Elm extract as active ingredients | |
| JP4136203B2 (en) | Skin preparation for external use | |
| JP3793612B2 (en) | Topical skin preparation | |
| JP2016188180A (en) | Composition containing specific ingredients | |
| JP2023517117A (en) | A topical composition containing a longan meat-containing mixed herbal extract and its use for the treatment or amelioration of skin ulcers | |
| JPH09208480A (en) | Substance P antagonist | |
| ITRM20130657A1 (en) | TREATMENT OF DERMATOPATHIES BY VEGETAL EXTRACT BY DAPHNE LAUREOLA | |
| JP3974003B2 (en) | Hair growth material and external preparation for skin containing the same | |
| JP2003335688A (en) | Bradykinin receptor antagonist | |
| EP0348215B1 (en) | Novel cosmetic and paramedicinal compositions | |
| KR20090126992A (en) | Camellia gourd (camellia seed shell powder) and its use | |
| JP6710408B2 (en) | Composition containing black ginger extract | |
| JPH0967245A (en) | Bath additive | |
| KR101115737B1 (en) | Composition containing coffee berry extracts or biter orange flower extracts | |
| JP2023518224A (en) | Topical composition containing longan meat-containing mixed herbal extract and its use for skin regeneration and treatment or amelioration of skin wounds | |
| JPH0310609B2 (en) | ||
| JP7617656B2 (en) | Composition containing specific ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060905 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061106 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071002 |